Oncology News and Research RSS Feed - Oncology News and Research Twitter

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.
NeoGenomics' revenue up 16.1% in first quarter 2014

NeoGenomics' revenue up 16.1% in first quarter 2014

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the first quarter of 2014. [More]
Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its pivotal trial of Captisol-enabled (propylene glycol-free) Melphalan met its primary end points. [More]
SIOG, EORTC update expert opinion on managing treatment for aged patients with NSCLC

SIOG, EORTC update expert opinion on managing treatment for aged patients with NSCLC

Half of all patients diagnosed with non-small cell lung cancer are 70 years of age or older, yet despite this high percentage, these elderly patients are not well represented in clinical trials. Therefore, the paucity of clinical data has made it difficult to reach evidence based clinical recommendations. [More]

HOPA Membership Awards winners for 2014 announced at 10th Annual Conference

The Hematology/Oncology Pharmacy Association (HOPA) announced the recipients of the 2014 HOPA Membership Awards at its 10th Annual Conference in March. HOPA Membership Awards recognize members who have shown outstanding achievement in their field. [More]

Novartis to buy Glaxosmithkline's oncology unit

The deal, worth billions, will also see Novartis sell its vaccines unit to Glaxo and partner with Glaxo on their consumer divisions. Novartis also said it will sell its animal health division to Eli Lily. [More]

Symposium focused on Surefire Medical's COSY clinical trial to be held at ECIO meeting

Surefire Medical, Inc. announced that a symposium focused on the Coiling vs. Surefire Infusion System in Y90 (COSY) clinical trial will be held during the European Conference on Interventional Oncology (ECIO) meeting taking place in Berlin, Germany April 23-26. T [More]

Bayer's Ciprofloxacin DPI receives FDA orphan drug designation for NCFB treatment

Bayer HealthCare today announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for its investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) for the treatment of non-cystic fibrosis bronchiectasis (NCFB). [More]

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed. [More]
IMPAKT breast cancer conference abstracts online

IMPAKT breast cancer conference abstracts online

Xenografts and mathematical modelling; liquid biopsy; nanotechnology; next generation genomics- Science is running fast and the impact of new technologies in the care of patients with breast cancer will be at the core of the sixth edition of the IMPAKT conference on translational research in breast cancer. [More]
OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

OncoSec Medical Inc., a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present an update of data from their Phase 2 melanoma study at the American Society of Clinical Oncology's 50th Annual Meeting, taking place May 30-June 3, 2014, at McCormick Place in Chicago, Illinois. [More]
First Edition: April 22, 2014

First Edition: April 22, 2014

Today's early morning highlights from the major news organizations, including marketplace news about the Novartis purchase of GlaxoSmithKline's oncology unit for $14.5 billion. [More]
Ockham to partner with Leukemia and Lymphoma Society to increase commitment to cancer philanthropy

Ockham to partner with Leukemia and Lymphoma Society to increase commitment to cancer philanthropy

Ockham Development will partner with the Leukemia and Lymphoma Society of North Carolina chapter during 2014 to increase its commitment to cancer-directed philanthropy and collaborate with the Society to support the company's personal health and fitness goals. [More]
Study evaluates stigma and public perceptions related to lung cancer

Study evaluates stigma and public perceptions related to lung cancer

It's not uncommon these days to find a colored ribbon representing a disease. A pink ribbon is well known to signify breast cancer. But what color ribbon does one think of with lung cancer? [More]

VACC designs new program to educate industry professionals on vascular access

Understanding the needs of health providers and their interaction with patients is paramount to the role of the employees of ICU Medical which provides clinicians around the world with innovative and cost-effective solutions for clinical needs. [More]

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed. [More]
Researchers develop simple assay that reveals evolutionary relationships among various tumor sites within patient

Researchers develop simple assay that reveals evolutionary relationships among various tumor sites within patient

​The process of metastasis - a tumor's ability to spread to other parts of the body - is still poorly understood. It is not easy to determine whether metastasis began early or late in the development of the primary tumor or whether individual metastatic sites were seeded directly from the original tumor or from an intermediate site. [More]

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML). [More]

BRI scientists receive grant to study new approach to blocking metastatic breast cancer

Benaroya Research Institute at Virginia Mason recently received a grant to research how blocking a particular molecule in metastatic breast cancer reduces both the growth of primary tumors and the number of lung metastases. [More]
Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate. [More]
Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered a molecule, or biomarker, called CD61 on the surface of drug-resistant tumors that appears responsible for inducing tumor metastasis by enhancing the stem cell-like properties of cancer cells. [More]